Secondary Stock OfferingsBy The Online Investor Staff, updated Sat., Sep. 19, 7:19 AM
|This Slide: #5 of 25|
Slide #5. NuCana plc — Secondary Offering
NuCana plc (NASDAQ:NCNA)
Date of Pricing:
Price Per Share:
Secondary Offering Details:
NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that it has commenced an underwritten public offering of its American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of NuCana. In addition, NuCana expects to grant the underwriters a 30-day option to purchase up to an additional 15% of its ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by NuCana. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. -updated 9/17- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the pricing of an underwritten public offering of 15,555,556 American Depositary Shares ("ADSs") at a price to the public of $4.50 per ADS, for total gross proceeds of approximately $70.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. Each ADS represents one ordinary share of NuCana. In addition, NuCana has granted the underwriters a 30-day option to purchase up to 2,333,333 additional ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs in the offering will be sold by NuCana. The offering is expected to close on or about September 21, 2020, subject to the satisfaction of customary closing conditions.
NuCana is a clinical-stage biopharmaceutical company developing a portfolio of new medicines to treat cancer. Co. develops anti-cancer medicines for ovarian, biliary, pancreatic, colorectal, haematology, oncology, and breast cancers. Co. produces oncology medicines using a proprietary technology platform for cancer patients. Co.'s most advanced ProTide candidates, Acelarin® and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Co. has retained worldwide rights to these lead product candidates as well as Co.'s preclinical product candidates, all of which Co. refers to as ProTides.
Open the NCNA Page at The Online Investor »
Strong Buy (4.00 out of 4)
(ranked higher than approx. 87% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite